Gabriel Sciences, LLC

Gabriel Sciences is a biotech company with the mission to advance the treatment and understanding of mental illness through its translational research, including collaborative opportunities with academic medicine. Founder David Pickar MD is former Chief of the Experimental Therapeutics Branch at National Institute of Mental Health (NIMH) and currently holds adjunct appointments as Professor of Psychiatry at Johns Hopkins University School of Medicine and the Uniformed Services University of the Health Sciences. Gabriel Sciences has been the recipient of NIH SBIR Phase I and Phase II grants for the development of a clinical DNA database enabling predictors of antipsychotic drug response. The current antidepressant program, which is a collaborative project with academic medicine, adds to Gabriel Sciences’ portfolio of drug development for the treatment of mental illness.

Press Release

Off-label Medicine Combinations are Predominant Treatment of Schizophrenics According to PLoS Article from Gabriel Sciences

Gabriel Sciences Receives NIH SBIR Grant for Development of Antidepressant